On October 9, 2025 Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, reported that its half-yearly financial report as of June 30, 2025 has been filed with the Financial Markets Authority (Press release, Oncodesign Precision Medicine, OCT 9, 2025, View Source [SID1234656548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The report includes:

The statement by the responsible person;
The management report;
The consolidated financial statements;
The various reports by the statutory auditors.
It also includes the company’s cash position. As of June 30, 2025, OPM had cash of €2.45 million. This amount does not include the €1.10 million research tax credit refund received in July 2025, nor the €0.22 million in repayable advances granted for the OncoSNIPE project.

This cash position does not take into account future revenues relating to potential future revenues, milestones and up-fronts for its products developed in existing or future partnerships, nor the amounts of public funding still to be received. Without any funding inflows in the coming weeks, OPM’s cash horizon is December 2025. However, several discussions are underway with potential partners, particularly regarding OPM-201.

The report is available (French only) on the OPM website, www.oncodesign.com, under the Investors / Regulated Information section.